PHATHOM PHARMACEUTICALS, INC. Revenue
PHATHOM PHARMACEUTICALS, INC. (PHAT) reported Revenue of $74.27 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement
us-gaap:Revenues · last filed 2026-07-30
- PHATHOM PHARMACEUTICALS, INC. revenues for the quarter ending 2026-06-30 was $74.27M, a 88.02% increase year-over-year.
- PHATHOM PHARMACEUTICALS, INC. revenues for the quarter ending 2026-03-31 was $58.30M, a 104.43% increase year-over-year.
- PHATHOM PHARMACEUTICALS, INC. revenues for the quarter ending 2025-12-31 was $57.58M, a 94.12% increase year-over-year.
- PHATHOM PHARMACEUTICALS, INC. revenues for the quarter ending 2025-09-30 was $49.50M, a 202.74% increase year-over-year.
- PHATHOM PHARMACEUTICALS, INC. revenues for fiscal 2025 was $175.11M, a 216.93% increase from fiscal 2024.
- PHATHOM PHARMACEUTICALS, INC. revenues for fiscal 2024 was $55.25M, a 8001.47% increase from fiscal 2023.
- PHATHOM PHARMACEUTICALS, INC. revenues for fiscal 2023 was $682.00K.
- PHATHOM PHARMACEUTICALS, INC. revenues for fiscal 2022 was $0.00.
| Period end | Revenues 3 month | Revenues 6 month | Revenues 9 month | Revenues 12 month |
|---|---|---|---|---|
| 2026-06-30 | $74.27M 10-Q · filed 2026-07-30 | $132.57M 10-Q · filed 2026-07-30 | $190.16M derived: sum of 3 quarters · filed 2026-07-30 | $239.66M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $58.30M 10-Q · filed 2026-04-30 | $115.89M derived: sum of 2 quarters · filed 2026-04-30 | $165.39M derived: sum of 3 quarters · filed 2026-04-30 | $204.89M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $57.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $107.09M derived: sum of 2 quarters · filed 2026-02-26 | $146.59M derived: sum of 3 quarters · filed 2026-07-30 | $175.11M 10-K · filed 2026-02-26 |
| 2025-09-30 | $49.50M 10-Q · filed 2025-10-30 | $89.01M derived: sum of 2 quarters · filed 2026-07-30 | $117.53M 10-Q · filed 2025-10-30 | $147.19M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $39.50M 10-Q · filed 2026-07-30 | $68.02M 10-Q · filed 2026-07-30 | $97.69M derived: sum of 3 quarters · filed 2026-07-30 | $114.04M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $28.52M 10-Q · filed 2026-04-30 | $58.18M derived: sum of 2 quarters · filed 2026-04-30 | $74.53M derived: sum of 3 quarters · filed 2026-04-30 | $81.86M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $29.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $46.02M derived: sum of 2 quarters · filed 2026-02-26 | $53.34M derived: sum of 3 quarters · filed 2026-02-26 | $55.25M 10-K · filed 2026-02-26 |
| 2024-09-30 | $16.35M 10-Q · filed 2025-10-30 | $23.68M derived: sum of 2 quarters · filed 2025-10-30 | $25.59M 10-Q · filed 2025-10-30 | $26.27M derived: sum of 4 quarters · filed 2025-10-30 |
| 2024-06-30 | $7.32M 10-Q · filed 2025-08-07 | $9.24M 10-Q · filed 2025-08-07 | $9.92M derived: sum of 3 quarters · filed 2025-08-07 | $9.92M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $1.91M 10-Q · filed 2025-05-01 | $2.59M derived: sum of 2 quarters · filed 2025-05-01 | $2.59M derived: sum of 3 quarters · filed 2025-05-01 | $2.59M derived: sum of 4 quarters · filed 2025-05-01 |
| 2023-12-31 | $682.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $682.00K derived: sum of 2 quarters · filed 2025-03-06 | $682.00K derived: sum of 3 quarters · filed 2025-03-06 | $682.00K 10-K · filed 2025-03-06 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $0.00 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $0.00 10-Q/A · filed 2024-06-14 | |||
| 2022-12-31 | $0.00 10-K/A · filed 2024-06-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |